A Delhi court has delivered a significant legal relief to Aurobindo Pharma by clearing Sarath Chandra Reddy of charges related to a liquor scam case. The court's decision removes potential legal uncertainties that could have impacted the pharmaceutical company's operations and leadership structure.

Court Decision Details

The Delhi court's ruling in favor of Sarath Chandra Reddy marks the conclusion of legal proceedings that had been pending against him in connection with liquor scam allegations. This judicial outcome provides clarity on the legal status of the Aurobindo Pharma leadership member.

Impact on Company Operations

The court's decision to clear Reddy of the charges eliminates a potential regulatory concern for Aurobindo Pharma. Legal issues involving key personnel can often create operational challenges and regulatory scrutiny for pharmaceutical companies, making this favorable outcome significant for the organization's continued business activities.

Legal Proceedings Conclusion

With the Delhi court's ruling, the liquor scam case against Sarath Chandra Reddy has reached its conclusion. This development allows the pharmaceutical company to move forward without the uncertainty that pending legal matters typically create for corporate leadership and business operations.

Aurobindo Pharma 's wholly owned subsidiary Eugia Pharma Specialities Limited has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus Tablets across four dosage strengths. This regulatory milestone opens access to a substantial US$ 78 million market opportunity.

Product Specifications and Approval Details

The USFDA approval covers Everolimus Tablets in 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg dosages, which are bioequivalent and therapeutically equivalent to Novartis Pharmaceuticals Corp's reference listed drug Zortress Tablets. The approval has been received from Eugia Unit-I facility.

Market Opportunity and Commercial Strategy

The approved product targets an estimated market size of US$ 78 million for the twelve months ending December 2025, according to IQVIA MAT data. The company plans to launch the product in Q1 FY27, positioning itself in the competitive US generic pharmaceutical market.

Therapeutic Applications

Everolimus Tablets are indicated for prophylaxis of organ rejection in adult patients undergoing kidney and liver transplants. For kidney transplant patients at low-moderate immunologic risk, the medication is used in combination with basiliximab, cyclosporine, and corticosteroids. For liver transplant patients, it is administered no earlier than 30 days post-transplant in combination with tacrolimus and corticosteroids.

Strategic Significance for Eugia Pharma

This approval represents the 184th ANDA approval for Eugia Pharma Specialities Group facilities, including 10 tentative approvals received. The milestone strengthens the company's portfolio in oncology oral and sterile specialty products, demonstrating its regulatory expertise and manufacturing capabilities in the US market.